Court :
THE AUTHORITY FOR ADVANCE RULINGS (INCOME TAX) NEW DELHI
Brief :
Where the applicant is in the business of providing bioanalytical services to various pharmaceutical companies around the world, the consideration/fee paid by the Indian pharmaceutical companies to the applicant in respect of bioequivalence tests conducted by it is in the nature of ‘business profits’ under article 7 of the Indo-Canada DTAA and the same is not taxable in India as the applicant does not have a PE in India.
Citation :
Anapharm Inc, In re:
AAR NO. 746 of 2008
September 11, 2008
Subscribe to CCI PRO for unlimited access
Already a PRO member? Login here for an ad-free experience.
DT & Audit (Exam Oriented Fastrack Batch) - For May 26 Exams and onwards Full English